Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 108.27% | 113.00% | -2,033.69% | -3,059.62% | -33,680.46% |
| Total Depreciation and Amortization | 36.60% | 41.65% | 53.99% | 37.88% | 24.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.23% | -94.50% | 515.75% | 397.26% | 471.40% |
| Change in Net Operating Assets | -676.24% | -236.70% | -2,262.89% | -59.00% | 208.65% |
| Cash from Operations | -136.24% | -114.06% | -88.66% | -39.43% | 18.31% |
| Capital Expenditure | 68.51% | 72.82% | 41.94% | 25.71% | -13.23% |
| Sale of Property, Plant, and Equipment | -50.70% | -39.61% | -13.48% | 495.52% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 50.70% | -6.94% | -17.15% | -87.62% | -80.20% |
| Cash from Investing | 44.67% | -0.63% | 25.68% | -7.50% | -19.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 423.56% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -1,452.00% | -583.74% | -- |
| Cash from Financing | -11.72% | -15.92% | 2,980.44% | 1,324.76% | 2,789.30% |
| Foreign Exchange rate Adjustments | 67.46% | 8.39% | 114.45% | 110.73% | 67.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -998.23% | -360.33% | -477.43% | -12.36% | 174.39% |